NCT01827202View on ClinicalTrials.gov

RAS Quantification in Patients With Aliskiren or Candesartan

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
HypertensionChronic Kidney DiseaseProteinuria
Interventions
OTHER

RAS blockade discontinuation

In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen

DRUG

Aliskiren

DRUG

Candesartan

Trial Locations (1)

1090

Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01827202 - RAS Quantification in Patients With Aliskiren or Candesartan | Biotech Hunter | Biotech Hunter